thrombocytopenia after radiotherapy and chemotherapy
Conditions
Interventions
Treatment group:thrombocytopenia with “Injection of Megakaryocyte Progenitor Cells from Umbilical Cord Blood” after radiotherapy and chemotherapy.
Sponsors
Institute of Transfusion Medicine, The Academy of Military Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 70 years old, open to men and women; 2. within one month after cancer radiotherapy and chemotherapy; 3. ECOG grades 0 or 1, expected survival time is more than or equal to three months; 4. Subjects are thrombocytopenia patients caused by cancer radiotherapy and chemotherapy; 5. platelet, which is more than 20*10^9/L and less than 50*10^9/L; 6. Results of liver and renal function are in normal or basic normal situation; 7. There is no infusion contraindication about injection of umbilical cord blood megakaryocyte progenitor cells; 8. understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. thrombocytopenia without cancer radiotherapy and chemotherapy; 2. Sternum or pelvis had received radiotherapy; 3. Patients with primary disease in important organs(liver, kidney), patients accompanied by the immune system disease, serious infections, mental disorders or organ transplant recipients; 4. pregnant, breast-feeding women; 5. Patients did not sign informed consent form; 6. infusion contraindication about injection of umbilical cord blood megakaryocyte progenitor cells.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time and response to platelet increasing; | — |
Countries
China
Contacts
Public ContactPei Xuetao
Outcome results
None listed